Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Japan Tissue Engineering Co., Ltd. ( (JP:7774) ) has provided an update.
Japan Tissue Engineering reported non-consolidated net sales of ¥2.18 billion for the year ended March 31, 2026, down 11.1% year on year, with an operating loss of ¥549 million and a net loss of ¥734 million, deepening from the prior year. Total assets fell to ¥5.68 billion and net assets to ¥5.09 billion, while the company again decided not to pay dividends and flagged ongoing earnings volatility tied to external factors.
Despite the weak results, the company projects a sharp rebound for the year ending March 31, 2027, forecasting net sales of ¥3.07 billion and a return to profitability with ¥100 million in net income. Management did not provide a midyear forecast due to the sensitivity of performance to external conditions, underscoring both the risk profile of its regenerative medicine business and the potential upside for investors if demand and operating leverage improve as expected.
More about Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd., listed on the Tokyo Stock Exchange Growth market under code 7774, operates in the regenerative medicine and tissue engineering field. The company focuses on developing and selling cell and tissue-based medical products, targeting niche healthcare segments where advanced regenerative therapies can drive long-term growth despite earnings volatility.
Average Trading Volume: 211,601
Technical Sentiment Signal: Sell
Current Market Cap: Yen21.69B
For a thorough assessment of 7774 stock, go to TipRanks’ Stock Analysis page.